Ting Yang1, Min Lu1, Lingyue Ma1, Ying Zhou1, Yimin Cui2. 1. Department of Pharmacy, Peking University First Hospital, Beijing, 100034, People's Republic of China. 2. Department of Pharmacy, Peking University First Hospital, Beijing, 100034, People's Republic of China. cuiymzy@126.com.
Abstract
PURPOSE: The aim of this study is to assess the efficacy and tolerability of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to metformin in patients with type 2 diabetes mellitus (T2DM). METHODS: Literatures were searched from major electronic databases, as well as the Chinese State Food and Drug Administration and clinicaltrials.gov for unpublished studies. Only randomized controlled trials (RCTs) comparing canagliflozin with placebo in combination with metformin were included. Two reviewers independently selected studies, evaluated the risk of bias, and extracted data. The included RCTs were analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration. RESULTS: Six RCTs were chosen for the meta-analysis. Compared to placebo, canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) (-0.66% [-0.72%, -0.61%]). The proportion of patients who achieved target HbA1c was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 2.09% (100 mg/day) and 2.66% (300 mg/day) with canagliflozin was observed. Canagliflozin was found to improve β cell function in terms of homeostasis model assessment (HOMA2-%B) (15.59% [12.84%, 18.35%]). Higher incidences of genital mycotic infection/female and pollakiuria (increased urine frequency) were noted with canagliflozin compared with placebo-controlled groups. CONCLUSIONS: Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. Common adverse events (AEs) like genital mycotic infection/female and pollakiuria were identified.
PURPOSE: The aim of this study is to assess the efficacy and tolerability of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to metformin in patients with type 2 diabetes mellitus (T2DM). METHODS: Literatures were searched from major electronic databases, as well as the Chinese State Food and Drug Administration and clinicaltrials.gov for unpublished studies. Only randomized controlled trials (RCTs) comparing canagliflozin with placebo in combination with metformin were included. Two reviewers independently selected studies, evaluated the risk of bias, and extracted data. The included RCTs were analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration. RESULTS: Six RCTs were chosen for the meta-analysis. Compared to placebo, canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) (-0.66% [-0.72%, -0.61%]). The proportion of patients who achieved target HbA1c was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 2.09% (100 mg/day) and 2.66% (300 mg/day) with canagliflozin was observed. Canagliflozin was found to improve β cell function in terms of homeostasis model assessment (HOMA2-%B) (15.59% [12.84%, 18.35%]). Higher incidences of genital mycotic infection/female and pollakiuria (increased urine frequency) were noted with canagliflozin compared with placebo-controlled groups. CONCLUSIONS:Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. Common adverse events (AEs) like genital mycotic infection/female and pollakiuria were identified.
Entities:
Keywords:
Canagliflozin; Meta-analysis; Metformin; Type 2 diabetes
Authors: S Sha; D Devineni; A Ghosh; D Polidori; S Chien; D Wexler; K Shalayda; K Demarest; P Rothenberg Journal: Diabetes Obes Metab Date: 2011-07 Impact factor: 6.577
Authors: D Devineni; L Morrow; M Hompesch; D Skee; A Vandebosch; J Murphy; K Ways; S Schwartz Journal: Diabetes Obes Metab Date: 2012-02-08 Impact factor: 6.577
Authors: F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122
Authors: Anastasios Tentolouris; Panayotis Vlachakis; Evangelia Tzeravini; Ioanna Eleftheriadou; Nikolaos Tentolouris Journal: Int J Environ Res Public Health Date: 2019-08-17 Impact factor: 3.390